Desensitization to febuxostat: report of two cases

Given the severity of the previous adverse reactions and the presence of HLA-B 5801, allopurinol reintroduction was contraindicated. [...]the patient underwent desensitization to febuxostat, performed as outlined in Table I. However, on the third day of desensitization, the patient developed delayed urticaria, 3 hours after the last administration, and febuxostat administration was interrupted. The patient was able to tolerate 60 mg of febuxostat into 3 divided doses for 8 days. Because no skin lesions relapsed, on day 23 the dose was increased to 70 mg and on day 25 the target dose of 80 mg was reached.\n00 0.01 1 0.01 10 0.00 4 4 16 19 0.00 4 4 16